Edgestream Partners L.P. Raises Stock Holdings in Zoetis Inc. $ZTS

Edgestream Partners L.P. boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 176.2% in the first quarter, Holdings Channel.com reports. The fund owned 77,506 shares of the company’s stock after acquiring an additional 49,448 shares during the quarter. Edgestream Partners L.P.’s holdings in Zoetis were worth $9,162,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Kentucky Retirement Systems increased its stake in Zoetis by 47.3% in the first quarter. Kentucky Retirement Systems now owns 41,281 shares of the company’s stock worth $4,880,000 after purchasing an additional 13,263 shares during the period. Oddo BHF Asset Management Sas boosted its stake in shares of Zoetis by 42.3% during the first quarter. Oddo BHF Asset Management Sas now owns 67,557 shares of the company’s stock valued at $7,986,000 after purchasing an additional 20,088 shares during the period. Strategic Investment Advisors MI purchased a new stake in shares of Zoetis during the first quarter valued at $275,000. Ashton Thomas Securities LLC grew its holdings in shares of Zoetis by 9.9% in the first quarter. Ashton Thomas Securities LLC now owns 21,718 shares of the company’s stock worth $2,567,000 after purchasing an additional 1,952 shares during the last quarter. Finally, South Dakota Investment Council grew its holdings in shares of Zoetis by 77.2% in the first quarter. South Dakota Investment Council now owns 220,819 shares of the company’s stock worth $26,103,000 after purchasing an additional 96,234 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Insiders Place Their Bets

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. TD Cowen reduced their price objective on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. JPMorgan Chase & Co. lowered their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. UBS Group dropped their target price on Zoetis from $99.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday. Finally, Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $118.33.

Zoetis Stock Performance

ZTS stock opened at $77.89 on Thursday. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48. The firm has a market cap of $32.66 billion, a price-to-earnings ratio of 12.92, a PEG ratio of 1.21 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm has a 50-day simple moving average of $77.21 and a two-hundred day simple moving average of $103.02.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.87 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.